1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA).
This omnibus solicitation supports small businesses in conducting research and development (R&D) for innovative technologies that align with the missions of NIH, CDC, and FDA to enhance human health. Clinical decision support software falls under biomedical innovation. This specific announcement is for projects that do NOT involve clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-based, for-profit small businesses with fewer than 500 employees. The Principal Investigator must be primarily employed by the small business. Confirm the full requirements in the official notice before applying.
The current listing shows varies by phase and institute, Phase I up to $300,000, Phase II up to $2,000,000+ (for specific topics with waivers). Verify award ceilings, matching requirements, and allowable costs in the official notice.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH Small Business Innovation Research (SBIR) Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This grant encourages small businesses to develop innovative technologies in biomedical research, including digital health tools, medical devices, and other health-related innovations. It provides non-dilutive funding for early-stage R&D.
Small Business Innovation Research (SBIR) PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-23-230) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program supports small businesses in developing innovative technologies in biomedical research, including clinical decision support tools and other health IT solutions. It funds feasibility studies and research and development needed for commercialization.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read articleBloomberg Philanthropies committed $150 million on October 20, 2026 to its Overdose Prevention Initiative, adding Washington state, continuing in Kentucky, New Jersey, New Mexico, North Carolina and Wisconsin, and exiting the two original 2018 states. The money flows through state partnerships, not an open call. Here is how organizations in those states can actually engage.
Read article